Zacks Investment Research downgraded shares of Vascular Biogenics (NASDAQ:VBLT) from a hold rating to a sell rating in a research report released on Saturday morning.
According to Zacks, “Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. “
VBLT has been the subject of several other research reports. ValuEngine lowered Vascular Biogenics from a sell rating to a strong sell rating in a report on Friday, March 9th. Piper Jaffray Companies lowered Vascular Biogenics from an overweight rating to a neutral rating and set a $4.00 price objective for the company. in a report on Thursday, March 8th. Chardan Capital lowered Vascular Biogenics from a buy rating to a neutral rating and cut their price objective for the company from $25.00 to $3.00 in a report on Thursday, March 8th. HC Wainwright set a $3.00 price objective on Vascular Biogenics and gave the company a hold rating in a report on Thursday, March 22nd. Finally, JMP Securities lowered Vascular Biogenics from an outperform rating to a market perform rating in a report on Thursday, March 8th. Two investment analysts have rated the stock with a sell rating and four have given a hold rating to the stock. Vascular Biogenics presently has a consensus rating of Hold and a consensus price target of $3.19.
Shares of Vascular Biogenics opened at $2.15 on Friday, Marketbeat Ratings reports. The firm has a market capitalization of $65.77 million, a PE ratio of -5.81 and a beta of -1.69. Vascular Biogenics has a fifty-two week low of $2.01 and a fifty-two week high of $9.05.
Vascular Biogenics (NASDAQ:VBLT) last announced its quarterly earnings data on Thursday, May 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.03). The firm had revenue of $0.16 million during the quarter. analysts forecast that Vascular Biogenics will post -0.79 EPS for the current year.
Institutional investors have recently made changes to their positions in the company. IFP Advisors Inc raised its position in shares of Vascular Biogenics by 339.7% during the fourth quarter. IFP Advisors Inc now owns 19,567 shares of the biopharmaceutical company’s stock worth $139,000 after purchasing an additional 15,117 shares during the period. Alps Advisors Inc. acquired a new stake in shares of Vascular Biogenics during the fourth quarter worth $234,000. ARK Investment Management LLC acquired a new stake in shares of Vascular Biogenics during the fourth quarter worth $302,000. Finally, Raymond James & Associates raised its position in shares of Vascular Biogenics by 71.5% during the fourth quarter. Raymond James & Associates now owns 55,466 shares of the biopharmaceutical company’s stock worth $394,000 after purchasing an additional 23,124 shares during the period. 7.26% of the stock is currently owned by institutional investors.
Vascular Biogenics Company Profile
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.
Get a free copy of the Zacks research report on Vascular Biogenics (VBLT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.